Panel Discussion: Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation

• What are the most fit-for-purpose recent innovations in liquid biopsy biomarkers, and how can these be robustly validated and integrated into clinical trial designs?  
• How can drug-diagnostic stakeholders build collaborative, scalable frameworks to advance liquid biopsy technologies, particularly in improving standardization, and harmonization? And who should contribute to this framework?

Speakers:

Carol Pena

Associate Vice President, Companion Diagnostic Development

Merck

Zheng Feng

Head, Clinical Genomics, Clinical Measurements Sciences

EMD Serono, the Healthcare Business of Merck KGaA, Darmstadt, Germany

Jarema Kochan

Senior Director, Clinical Biomarkers, Clinical Development

Eikon Therapeutics

Kris Sachsenmeier

Vice President, Translational Sciences

Compass Therapeutics